Overcome AI anxiety today. AI anxiety is a growing psychological phenomenon affecting millions of professionals worldwide as artificial intelligence rapidly transforms the workplace. You wake up in the morning, check the news, and see another headline about AI automating jobs. Your stomach tightens as you wonder: 'Am I next?'

Psychedelics in 2025: Psychedelic medicine in the US has reached a crucial inflection point as of May 2025, with ketamine firmly established in mainstream treatment, psilocybin progressing toward potential FDA approval, and MDMA facing regulatory setbacks. Ketamine received expanded FDA approval as monotherapy for treatment-resistant depression in January 2025, while psilocybin therapy is accessible through licensed service centers in Oregon and Colorado with COMPASS Pathways' Phase 3 trial results expected by mid-2025. MDMA faces additional years of development after the FDA rejected Lykos Therapeutics' application in August 2024.

Psychedelic research is experiencing a resurgence. In the late 60s and early 70s, psychedelic research was a booming field. But after a series of political crackdowns, it dropped off considerably. Recently, however, there has been a psychedelic research comeback, a resurgence of interest in the potential of psychedelic drugs to treat mental health issues such as depression and anxiety. With more studies being conducted and an increasing acceptance of psychedelics’ therapeutic benefits, we may be on the cusp of a new era in psychedelic research. In this blog post, we’ll take a look at how psychedelics are being used in scientific research today and explore some of the potential applications for these powerful substances.

The Psychedelic Comeback Reaches Mainstream Medicine. The psychedelic comeback is transforming mental healthcare in 2025, with MDMA, psilocybin, and ketamine therapy now available in 32 states. After decades of prohibition, these powerful substances have reemerged as legitimate treatment options for depression, PTSD, and anxiety disorders—backed by impressive clinical results and unprecedented regulatory support. Major insurers now cover psychedelic-assisted therapy for treatment-resistant depression and PTSD, making these breakthrough treatments accessible to millions of Americans who previously had limited options. This psychedelic comeback represents the most significant paradigm shift in mental health treatment since the introduction of SSRIs in the 1980s.

Finding the right balance of peak experience, effective practice, and flow states is essential for sustained gains in the long run. Why? People are needy. We want it all; we want it now; we want it to last forever; and we want it for free. This is the calculus of biology, but never confuse short-term appetites with lifelong strategy. Real gains have a half-life. They’re perishable. Preserving them requires effort, intelligence, and a strategy. To make our efforts productive over the long haul, we need the right combination of peak experiences, effective regular practice habits, and the ability to create flow states to accelerate the process.

Whether composing a tweet, an email, a blog post, a business case, an essay, or a book, you must connect powerfully and viscerally to what a reader stands to gain or lose by your proposition—real or imagined. Persuasive writing speaks to your reader’s visceral emotions, and more than just getting them to agree with you, it gets them moving in the same direction. Effectively, your idea becomes your reader’s idea and compels him or her to: start, stop, buy, act, change, invest, or avoid something you are saying. But how? Here are four things to think about when writing to persuade your audience.

The Neurolinguistic Programming community mourns the passing of Steve Andreas, a beloved figure in the field. He was a champion of Grass Roots NLP and helped many people learn to use the technology for their own benefit. His legacy will live on in the work he inspired others to produce, and his family can take comfort in knowing that his impact will continue to be felt for years to come.